Cost‐Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway
Based on the RSVpreF vaccine's list price in Norway, the seasonal vaccination program is cost-effective from both the healthcare and societal perspectives, considering a willingness-to-pay threshold of 500,000 NOK.
Authors
- Lise Beier Havdal (ORCID: https://orcid.org/0000-0001-7429-8119)
- Oddvar Solli (ORCID: https://orcid.org/0009-0007-7920-9913)
- David Ngaruiya Mwaura
- Christoffer Bugge (ORCID: https://orcid.org/0000-0002-0766-2870)
- Francisco Oteiza (ORCID: https://orcid.org/0000-0002-3747-9786)
- Øyvind Husby
- K.I. Lie
- Susanne Gerda Værnø
- Maren Gillebo
Institutions
- Pfizer (United States) (US)
- Akershus University Hospital (NO)
- 657 Oslo (NO)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/irv.70161
- Citations
- 1
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Pfizer